Compare iShares MSCI Singapore ETF (EWS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs Novo Nordisk A/S — how do they compare? iShares MSCI Singapore ETF trades at $33.82, while Novo Nordisk A/S trades at $46.45 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while iShares MSCI Singapore ETF pays none, and iShares MSCI Singapore ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| EWS | NVO | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $33.92 | $63.98 |
52-Week Low | $26.71 | $35.29 |
Market Cap | — | $207.85B |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWS, the iShares MSCI Singapore ETF, trades at $33.64, up 1.42% and hitting a new 52-week high. Technical indicators show a bullish moving average trend but overbought oscillators. The ETF benefits from Singapore's economic resilience, AI-driven growth, and a 3.97% dividend yield, with institutional interest rising as Amundi increased holdings by 4.8% in Q2 2026.
Outlook is positive due to strong momentum and structural growth in Singapore's financial and tech sectors. Risks include concentrated exposure to financials (54% of holdings) and sensitivity to Asian market volatility. The ETF offers diversification but requires monitoring for overextension near all-time highs.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
